Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Factors Affecting Protein-Drug Binding: Drug Interactions

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Climbing to the Summit of Guideline Directed Therapy of Heart Failure:A Slippery Slope.

The American journal of cardiology·2025

Same author

Assessment and Follow-Up of the Aortic Root by 2-Dimensional Echocardiography.

The American journal of cardiology·2024

Same author

Elevated Lp(a): Guidance for Identifying and Managing Patients.

Southern medical journal·2024

Same author

Should We Routinely Take a Closer Look During Percutaneous Coronary Intervention: What Are the Roles of Intravascular Ultrasound and Optical Coherence Tomography?

The American journal of cardiology·2023

Same author

Right Ventricular Function in Acute Myocardial Infarction: Is It Important and How Should We Assess It?

The American journal of cardiology·2023

Same author

Reduced Cancer Incidence and Mortality After Acute Coronary Syndrome: Fact, Fiction, or Artifact?

The American journal of cardiology·2023

Search research articles

Related Experiment Videos

Potential Interaction between clopidogrel and proton pump inhibitors.

Patricia A Howard¹, James L Vacek

¹School of Pharmacy, The University of Kansas Hospital and Medical Center, Kansas City, Kansas, USA. phoward@kumc.edu

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions

|November 26, 2009

Summary

This summary is machine-generated.

Proton pump inhibitors (PPIs) may reduce clopidogrel

Related Experiment Videos

Area of Science:

Cardiology and Pharmacology

Background:

Clopidogrel is a critical antiplatelet medication used in acute coronary syndromes and after stent implantation.
Dual antiplatelet therapy (clopidogrel with aspirin) reduces thrombotic events but increases bleeding risk, especially gastrointestinal (GI) bleeds.
Proton pump inhibitors (PPIs) are frequently prescribed to mitigate GI bleeding risk in patients on antiplatelet therapy.

Purpose of the Study:

To evaluate the potential adverse interaction between proton pump inhibitors (PPIs) and clopidogrel.
To assess whether PPIs diminish the antiplatelet efficacy of clopidogrel.

Main Methods:

Review of current scientific literature and clinical evidence regarding the clopidogrel-PPI interaction.
Analysis of studies investigating the impact of PPIs on clopidogrel's antiplatelet effects.

Main Results:

Emerging evidence suggests that PPIs may interfere with clopidogrel's antiplatelet action.
This potential interaction could lead to a diminished therapeutic benefit of clopidogrel.
The clinical significance and extent of this interaction are still under investigation.

Conclusions:

The combination of clopidogrel and PPIs requires cautious use due to potential reduced antiplatelet efficacy.
Further research is necessary to fully elucidate the drug interaction and its clinical implications.
Determining if this interaction is a drug-class effect is crucial for clinical practice guidelines.